1,10-Dihydro-1,2,10-triaza-cyclopenta[a]fluorene

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 1,10-Dihydro-1,2,10-triaza-cyclopenta[a]fluorene
• 化学式: C₁₃H₉N₃
• 分子量: 207.235
• InChiKey: HBLHKDYXRQVUNT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  16.0
• 可旋转键数：
  0.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  44.47
• 氢给体数：
  2.0
• 氢受体数：
  1.0

反应信息

• 作为产物：
  描述：

  2,3,4,9-四氢-1H-咔唑-1-酮 在 一水合肼 作用下， 以 乙醇 为溶剂， 反应 11.0h， 生成 1,10-Dihydro-1,2,10-triaza-cyclopenta[a]fluorene
  参考文献：
  名称：

  Sekar, M.; Prasad, K. J. Rajendra, Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1998, vol. 37, # 3, p. 314 - 317

  摘要：

  DOI：

文献信息

• Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
  申请人：Vanotti Ermes

  公开号：US20060264493A1

  公开（公告）日：2006-11-23

  The present invention provides a method for treating diseases caused by and/or associated with an altered protein kinase activity which comprises administering to a mammal in need thereof an effective amount of a tetracyclic pyrazole. The invention also provides specific tetracyclic pyrazole derivatives, useful intermediates, a library comprising at least two of them, a process for their preparation and the pharmaceutical compositions containing them, which are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, cell proliferative disorders, viral infections, autoimmune diseases and neurodegenerative disorders.

  本发明提供了一种治疗由改变的蛋白激酶活性引起和/或相关的疾病的方法，包括向需要治疗的哺乳动物中给予有效量的四环吡唑。本发明还提供了特定的四环吡唑衍生物、有用的中间体、包含至少两个四环吡唑衍生物的库、它们的制备方法以及含有它们的药物组合物，这些组合物对于治疗由改变的蛋白激酶活性引起和/或相关的疾病，如癌症、细胞增殖性疾病、病毒感染、自身免疫性疾病和神经退行性疾病非常有用。
• Indole Derivative and Use for Treatment of Cancer
  申请人：Nishikimi Yuji

  公开号：US20070254877A1

  公开（公告）日：2007-11-01

  The present invention relates to a compound represented by the formula wherein A is a benzene ring optionally having substituents, R 1 , R 2a and R 3 are each a hydrogen atom, a hydrocarbon group optionally having substituents or a heterocyclic group optionally having substituents, R 1 and R 2a may form a ring via X, when R 1 and R 2a form a ring via X, R 1 and R 2a are each a bond or a divalent C 1-5 acyclic hydrocarbon group optionally having substituents, and X is a bond, an oxygen atom, an optionally oxidized sulfur atom or an imino group optionally having a substituent, provided that R 1 , R 2a and X are not bonds at the same time, or a salt thereof, and an agent for inhibiting kinase (phosphorylation enzyme), which contains this compound or a prodrug thereof. The compound of the present invention has an inhibitory activity against kinase such as a vascular endothelial growth factor receptor (VEGFR) and the like, and is useful as an agent for the prophylaxis or treatment of cancer and the like.

  本发明涉及一种化合物，其表示为以下式子： 其中，A是苯环，可选地具有取代基，R1、R2a和R3分别是氢原子、可选地具有取代基的碳氢基团或可选地具有取代基的杂环基团，当R1和R2a通过X形成环时，R1和R2a可以是一个键或可选地具有取代基的双价C1-5非环烃基团，X是键、氧原子、可选地氧化的硫原子或可选地具有取代基的亚胺基团，前提是R1、R2a和X不同时为键，或其盐，以及一种抑制激酶（磷酸化酶）的药剂，其含有该化合物或其前药。 本发明的化合物具有对激酶（如血管内皮生长因子受体（VEGFR）等）的抑制活性，可用作预防或治疗癌症等疾病的药剂。
• A novel necroptosis inhibitor—necrostatin-21 and its SAR study
  作者：Zhijie Wu、Ying Li、Yu Cai、Junying Yuan、Chengye Yuan

  DOI：10.1016/j.bmcl.2013.06.073

  日期：2013.9

  An initial structure-activity relationship study of the novel necroptosis inhibitor Nec-21 was described. Any changes of the tetracyclic scaffold were detrimental for the activity. Introduction of a substituent to 7 or 8 position (e.g., cyano or methoxy group, respectively), would increase the activity. The 7 and 8-position disubstituted compound 17b was 35-fold as potent as the lead, while EC50 reached 14 nM. (C) 2013 Elsevier Ltd. All rights reserved.
• Velmurugan; Vijayasankar; Sekar, Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2013, vol. 52, # 3, p. 414 - 421
  作者：Velmurugan、Vijayasankar、Sekar

  DOI：——

  日期：——
• Sekar, M.; Prasad, K. J. Rajendra, Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1998, vol. 37, # 3, p. 314 - 317
  作者：Sekar, M.、Prasad, K. J. Rajendra

  DOI：——

  日期：——